State of Tennessee Treasury Department grew its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 5.3% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 1,673,694 shares of the biopharmaceutical company’s stock after purchasing an additional 84,059 shares during the period. State of Tennessee Treasury Department owned about 0.10% of Bristol-Myers Squibb worth $93,259,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently made changes to their positions in the company. Tradewinds Capital Management LLC lifted its holdings in shares of Bristol-Myers Squibb by 34.6% during the second quarter. Tradewinds Capital Management LLC now owns 1,945 shares of the biopharmaceutical company’s stock valued at $108,000 after purchasing an additional 500 shares during the last quarter. Blue Chip Partners Inc. lifted its holdings in shares of Bristol-Myers Squibb by 0.8% during the first quarter. Blue Chip Partners Inc. now owns 2,141 shares of the biopharmaceutical company’s stock valued at $116,000 after purchasing an additional 17 shares during the last quarter. Proficio Capital Partners LLC lifted its holdings in shares of Bristol-Myers Squibb by 29.6% during the first quarter. Proficio Capital Partners LLC now owns 2,204 shares of the biopharmaceutical company’s stock valued at $119,000 after purchasing an additional 504 shares during the last quarter. American National Bank lifted its stake in Bristol-Myers Squibb by 11.7% in the 2nd quarter. American National Bank now owns 2,144 shares of the biopharmaceutical company’s stock worth $119,000 after acquiring an additional 225 shares in the last quarter. Finally, Heritage Trust Co purchased a new stake in Bristol-Myers Squibb in the 1st quarter worth about $123,000. 68.97% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: This piece of content was reported by Community Financial News and is the property of of Community Financial News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.com-unik.info/2017/11/21/state-of-tennessee-treasury-department-has-93-26-million-stake-in-bristol-myers-squibb-company-bmy.html.
Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing the Zacks’ consensus estimate of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analyst estimates of $5.20 billion. Bristol-Myers Squibb had a net margin of 16.29% and a return on equity of 22.99%. The business’s revenue was up 6.7% on a year-over-year basis. During the same period in the prior year, the company posted $0.77 EPS. analysts expect that Bristol-Myers Squibb Company will post 2.99 earnings per share for the current year.
The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th were issued a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date of this dividend was Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is 61.42%.
In other news, SVP Joseph C. Caldarella sold 9,340 shares of the stock in a transaction dated Wednesday, September 6th. The stock was sold at an average price of $60.00, for a total transaction of $560,400.00. Following the transaction, the senior vice president now owns 46,297 shares of the company’s stock, valued at approximately $2,777,820. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.23% of the company’s stock.
Several equities research analysts recently issued reports on BMY shares. UBS AG reissued a “buy” rating and issued a $72.00 price objective (up from $62.00) on shares of Bristol-Myers Squibb in a research note on Friday, October 6th. Vetr raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $67.92 price objective for the company in a research note on Monday, October 9th. Zacks Investment Research downgraded Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. BMO Capital Markets reissued a “sell” rating and issued a $49.00 price objective on shares of Bristol-Myers Squibb in a research note on Monday, September 4th. Finally, Citigroup Inc. increased their price objective on Bristol-Myers Squibb to $72.00 and gave the stock a “buy” rating in a research note on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and eleven have given a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $64.93.
Bristol-Myers Squibb Company Profile
Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.
What are top analysts saying about Bristol-Myers Squibb Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bristol-Myers Squibb Company and related companies.